OxyContin Settlement Between Purdue and Sandoz Approved

Purdue Pharma L.P. et al. v. Sandoz Inc.

Case Number: 1:13-cv-07776-SHS (Dkt. 16)

Judge Stein approved the settlement between plaintiffs Purdue et al. and defendant Sandoz Inc. with respect to the U.S. Patents Nos. ­­­­8,309,060 (entitled “Abuse-proofed dosage form”) and 8,337,888 (entitled “Pharmaceutical formulation containing gelling agent”). These patents relate to the drug oxycodone, sold by Purdue as OxyContin. Sandoz agreed that the patents were valid and enforceable against its products, that its ANDA products infringed the claims asserted against it, and agreed not to make, have made, use offer to sell, sell, or import generic oxycodone products until an undisclosed terminal date. Plaintiffs agreed not to sue Sandoz for products authorized by a separate, confidential agreement.

The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.